Related Experiment Video
Updated: May 15, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic virus therapy for cancer: the first wave of translational clinical trials
Manish R Patel1, Robert A Kratzke
1Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minn., USA.
Abstract:
The field of oncolytic virus therapy, the use of live, replicating viruses for the treatment of cancer, has expanded rapidly over the past decade. Preclinical models have clearly demonstrated anticancer activity against a number of different cancer types. Several agents have entered clinical trials and promising results have led to late stage clinical development for some viruses. The early clinical trials have demonstrated that oncolytic viruses by themselves have potential to result in tumor regression. Engineering of viruses to express novel genes have also led to the use of these vectors as a novel form of gene therapy. As a result, interest in oncolytic virus therapy has gained traction. The following review will focus on the first wave of clinical translation of oncolytic virus therapy, what has been learned so far, and potential challenges ahead for advancing the field.
Insights
Oncolytic virus therapy uses live viruses to treat cancer, showing promise in preclinical and early clinical trials for tumor regression. Further research is needed to overcome challenges and advance this innovative cancer treatment.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Oncolytic virus therapy, utilizing live replicating viruses, has seen significant expansion.
- Preclinical models confirm anticancer activity across various cancer types.
- Several oncolytic virus agents have progressed to clinical trials.
Purpose of the Study:
- To review the initial clinical translation of oncolytic virus therapy.
- To summarize key learnings from early clinical studies.
- To identify challenges and future directions for the field.
Main Methods:
- Review of preclinical data demonstrating oncolytic virus efficacy.
- Analysis of early-phase clinical trial results.
- Examination of engineered viruses for gene therapy applications.
Main Results:
- Oncolytic viruses show potential for direct tumor regression in clinical settings.
- Virus engineering enables novel gene therapy applications.
- Promising results have led to late-stage clinical development for some agents.
Conclusions:
- Oncolytic virus therapy is a rapidly advancing field with demonstrated potential.
- Engineering viruses offers new therapeutic avenues.
- Addressing challenges is crucial for future clinical success.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...